Safety of tetrahydrocurcuminoids from turmeric (*Curcuma longa* L.) as a novel food pursuant to Regulation (EU) 2015/2283

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-Ernst, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Thomas Frenzel, Marina Heinonen, Rosangela Marchelli, Monika Neuhäuser-Berthold, Morten Poulsen, Miguel Prieto Maradona, Josef Rudolf Schlatter, Henk van Loveren, Reinhard Ackerl, Eirini Kouloura and Helle Katrine Knutsen

Abstract

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on tetrahydrocurcuminoids from turmeric (*Curcuma longa* L.) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. Tetrahydrocurcuminoids are derivatives of curcuminoids, produced chemically by hydrogenation of curcuminoids extracted from the rhizomes of *C. longa* L. The NF consists of more than 95% of tetrahydrocurcuminoids. The applicant proposed to use the NF in food supplements at a maximum dose of 300 mg/day for adults excluding pregnant and lactating women. Taking into account the composition of the NF and the proposed conditions of use, consumption of the NF is not nutritionally disadvantageous. There are no concerns regarding genotoxicity of the NF. Based on a 90-day oral toxicity study and a reproduction/developmental toxicity screening test performed with the NF, the Panel derives a safe level of 2 mg/kg body weight per day. For the target population this level corresponds to 140 mg/day, which is lower than the use level as proposed by the applicant. The Panel concludes that the NF, tetrahydrocurcuminoids from turmeric (*C. longa* L.), is safe for the target population at 140 mg/day.

© 2021 European Food Safety Authority. *EFSA Journal* published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

Keywords: novel foods, tetrahydrocurcuminoids, *Curcuma longa* L., turmeric, food supplement, safety

Requestor: European Commission

Question number: EFSA-Q-2020-00111

Correspondence: nda@efsa.europa.eu
Panel members: Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-Ernst, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri and Marco Vinceti.

Declaration of Interest: The declarations of interest of all scientific experts active in EFSA’s work are available at https://ess.efsa.europa.eu/doi/doiweb/doisearch.

Suggested citation: EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Frenzel T, Heinonen M, Marchelli R, Neuhäuser-Berthold M, Poulsen M, Prieto Maradona M, Schlatter JR, van Loveren H, Ackerl R, Kouloura E and Knutsen HK, 2021. Scientific Opinion on the safety of tetrahydrocurcuminoids from turmeric (Curcuma longa L.) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2021;19(12):6936, 16 pp. https://doi.org/10.2903/j.efsa.2021.6936

ISSN: 1831-4732

© 2021 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

The EFSA Journal is a publication of the European Food Safety Authority, a European agency funded by the European Union.
Table of contents

Abstract................................................................................................................................................... 1
1 Introduction.................................................................................................................................. 4
1.1 Background and Terms of Reference as provided by the requestor.................................................... 4
2 Data and methodologies ................................................................................................................ 4
2.1 Data............................................................................................................................................. 4
2.2 Methodologies............................................................................................................................... 4
3 Assessment................................................................................................................................... 4
3.1 Introduction .................................................................................................................................. 4
3.2 Identity of the NF.......................................................................................................................... 5
3.3 Production process ........................................................................................................................ 6
3.4 Compositional data ....................................................................................................................... 6
3.4.1 Stability ........................................................................................................................................ 8
3.5 Specifications ................................................................................................................................ 9
3.6 History of use of the NF and/or of its source ................................................................................... 9
3.7 Proposed uses and use levels and anticipated intake ........................................................................ 9
3.7.1 Target population .......................................................................................................................... 9
3.7.2 Proposed uses and use levels ......................................................................................................... 10
3.7.3 Exposure to undesirable substances ............................................................................................ 10
3.8 Absorption, distribution, metabolism and excretion (ADME) .............................................................. 10
3.9 Nutritional information ................................................................................................................... 10
3.10 Toxicological information ................................................................................................................ 10
3.10.1 Genotoxicity.................................................................................................................................. 11
3.10.2 Acute and subchronic toxicity ......................................................................................................... 12
3.10.3 Reproductive and developmental toxicity......................................................................................... 12
3.10.4 Human data.................................................................................................................................. 13
3.11 Allergenicity .................................................................................................................................. 13
4 Discussion .................................................................................................................................... 13
5 Conclusions................................................................................................................................... 14
5.1 Request for protection of proprietary data in accordance with Article 26 of Regulation (EU) 2015/228314 14
6 Steps taken by EFSA..................................................................................................................... 14
References............................................................................................................................................... 15
Abbreviations ........................................................................................................................................... 15
1. **Introduction**

1.1. **Background and Terms of Reference as provided by the requestor**

On 3 February 2020, the company Sabinsa Europe GmbH submitted a request to the Commission in accordance with Article 10 of Regulation (EU) No 2015/2283\(^1\) to place on the EU market tetrahydrocurcuminoids from turmeric (*Curcuma longa* L.).

Tetrahydrocurcuminoids from turmeric (*Curcuma longa* L.) are intended to be used in food supplements as defined in Directive 2002/46/EC of the European Parliament and of the Council.

The applicant has requested data protection according to the provisions of Article 26 of Regulation (EU) 2015/2283.

In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the European Food Safety Authority to provide a scientific opinion on tetrahydrocurcuminoids from turmeric (*Curcuma longa* L.).

2. **Data and methodologies**

2.1. **Data**

The safety assessment of this NF is based on data supplied in the application and information submitted by the applicant following EFSA requests for supplementary information.

Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation (EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/2469\(^2\).

A common and structured format on the presentation of NF applications is described in the EFSA guidance on the preparation and presentation of a NF application (EFSA NDA Panel, 2016). As indicated in this guidance, it is the duty of the applicant to provide all of the available (proprietary, confidential and published) scientific data, (including both data in favour and not in favour) that are pertinent to the safety of the NF.

This NF application includes a request for protection of proprietary data in accordance with Article 26 of Regulation (EU) 2015/2283. The data requested by the applicant to be protected comprise: all the analytical data and certifications, two bacterial reverse mutation assays (Indian Institute of Toxicology, 2004, unpublished; Innovis, 2012, unpublished), *in vitro* micronucleus assay (Bioneeds India Private Limited, 2019, unpublished), acute toxicity study (Indian Institute of Toxicology, 2003, unpublished), full study reports of a subchronic toxicity study and a reproduction/developmental toxicity screening test (Vipragen Biosciences, 2016a,b; Majeed et al., 2019) and a human study (Sabinsa Japan Corporation, 2011, unpublished).

2.2. **Methodologies**

The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA NDA Panel, 2016) and the principles described in the relevant existing guidance documents from the EFSA Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.

This assessment concerns only risks that might be associated with consumption of the NF under the proposed conditions of use, and is not an assessment of the efficacy of the NF with regard to any (claimed) benefit.

3. **Assessment**

3.1. **Introduction**

The NF falls under Article 3 of Regulation (EU) 2015/2283, that is, food with a new or intentionally modified molecular structure and food consisting of, isolated from, or produced from plants and their parts.

---

1. Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, p. 1–22.
2. Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
The NF which is the subject of the application is a white to pale yellow powder of tetrahydrocurcuminoids from turmeric (C. longa L.). The NF is produced by hydrogenation of curcuminoids from rhizomes of C. longa L. into tetrahydrocurcuminoids and consists of more than 95% of tetrahydrocurcuminoids. The NF is proposed to be used in food supplements. The target population is adults excluding pregnant and lactating women.

### 3.2. Identity of the NF

The NF is a powder of tetrahydrocurcuminoids obtained by extraction of curcuminoids from turmeric (rhizomes of C. longa L.) and hydrogenation into tetrahydrocurcuminoids.

*C. longa* is a plant of the Zingiberaceae family and rhizomes of this plant are used for the production of the NF. Common names of the plant include curcuma and turmeric. The raw material is obtained from cultivated sources. The identification of the plant material is performed based on macroscopic and microscopic characteristics of the rhizomes. Moreover, the presence of curcuminoids in ethanolic extracts of rhizomes is assessed by high-performance thin-layer chromatography (HPTLC).

Curcuminoids are constituted of curcumin (1\(E\),6\(E\))-1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (I), desmethoxycurcumin ((1\(E\),6\(E\))-1-(4-hydroxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) (II) and bisdesmethoxycurcumin ((1\(E\),6\(E\))-1,7-bis(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione) (III) with curcumin being the major compound, approximately 90% of the curcuminoid content in turmeric (EMA, 2018). Upon hydrogenation, curcuminoids are converted into tetrahydrocurcuminoids, which are the colourless hydrogenated compounds and specifically tetrahydrocurcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-dione), MW: 372 (IV) from curcumin, tetrahydrodesmethoxycurcumin 1-(4-hydroxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)-1,6-heptane-3,5-dione, MW: 342 (V) from desmethoxycurcumin and tetrahydrobisdesmethoxycurcumin (1,7-bis(4-hydroxyphenyl)-heptane-3,5-dione), MW: 312 (VI) from bisdesmethoxycurcumin. The identity of the three main constituents was demonstrated by HPLC/UV chromatography, \(^1\)H-NMR, \(^{13}\)C-NMR spectroscopy and mass spectrometry (Figure 1).

![Chemical structures, molecular formulae and CAS registry numbers of curcuminoids (I, II, III) and tetrahydrocurcuminoids (IV, V, VI)](https://www.efsa.europa.eu/efsajournal/5 EFSA Journal 2021;19(12):6936)
In the application dossier the NF is also denominated as Curcumin C3 Reduct®.

### 3.3. Production process

According to the information provided, the NF is produced in line with Good Manufacturing Practice (GMP), and food safety system 22000 (International Organization for Standardization (ISO) ISO 22000:2005; ISO TS 22002-1:2009 and Additional FSSC 22000 requirements V4.1). Information on the applied Hazard Analysis Critical Control Points (HACCP) plan was also provided.

The raw material, turmeric rhizomes, is initially cleaned with water, steamed and sun dried. Then turmeric rhizomes are pulverised and pelletised. Powder of rhizomes of *C. longa* is extracted to obtain an extract rich in curcuminoids (> 95% w/w dry basis). The Panel notes that the extract rich in curcuminoids is obtained following the traditional process used for the production of the food additive curcumin E 100. The extract is further concentrated and allowed to crystallise. Crystals are filtered, washed, filtered again and dried (loss on drying < 2%). Thereafter, the curcuminoids in the extract are hydrogenated into tetrahydrocurcuminoids, using palladium on carbon (Pd/C) as a catalyst. The solution is concentrated, allowed to crystallise, filtered and dried until loss on drying < 1%. The final dried material is milled, blended, sifted and packed into bags.

The Panel considers that the production process is sufficiently described and does not raise safety concerns.

### 3.4. Compositional data

The NF consists of more than 95% of tetrahydrocurcuminoids and in particular tetrahydrocucurmin, tetrahydrodesmethoxycurcumin and tetrahydrobidesmethoxycurcumin.

In order to confirm that the manufacturing process is reproducible and adequate to produce on a commercial scale a product with certain required characteristics, the applicant provided analytical information for ten batches of the NF (Table 1).

#### Table 1: Batch to batch analysis of the NF

| Parameter (Unit) | Batch number | Method of analysis |
|------------------|--------------|--------------------|
|                  | #1 | #2 | #3 | #4 | #5 | #6 | #7 | #8 | #9 | #10 |
| **Total tetrahydrocurcuminoids (% w/w dry basis)** | 95.73 | 95.77 | 96.23 | 95.42 | 95.18 | 97.83 | 95.95 | 95.8 | 96.8 | 95.41 | HPLC-UV (In-house method) |
| **Tetrahydrocurcumin (% w/w dry basis)** | 87.38 | 85.02 | 86.51 | 88.38 | 87.29 | HPLC-UV (In-house method) |
| **Tetrahydrodesmethoxycurcumin (% w/w dry basis)** | 6.23 | 6.92 | 6.71 | 6.12 | 6.16 | HPLC-UV (In-house method) |
| **Tetrahydrobidesmethoxycurcumin (% w/w dry basis)** | 0.24 | 0.38 | 0.36 | 0.20 | 0.21 | HPLC-UV (In-house method) |
| **Loss on drying (% w/w)** | 0.09 | 0.21 | 0.32 | Gravimetry (UPS 731) |
| Parameter (Unit) | Batch number | Method of analysis |
|------------------|--------------|--------------------|
|                  | #1  | #2  | #3  | #4  | #5  | #6  | #7  | #8  | #9  | #10 |
| Moisture (% w/w) |     |     |     |     | 0.35 | 0.35 | 0.25 | 0.19 | 0.34 |
| Ash (% w/w)      | 0.06 | 0.05 | 0.06 | 0.8 | 0.04 | 0.04 | 0.05 | 0.03 | 0.05 |
| Palladium (mg/kg) | 1.58 | 3.52 | 0.71 | 0.40 | 0.05 |
| Lead (mg/kg)     | 0.35 | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 |
| Arsenic (mg/kg)  | 0.35 | 0.67 | 0.56 | 0.69 | 0.6 | 0.26 | 0.31 | 0.29 | 0.26 |
| Cadmium (mg/kg)  | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 | < 0.2 |
| Mercury (mg/kg)  | < 0.02 | < 0.02 | < 0.02 | < 0.02 | < 0.02 | < 0.02 | < 0.02 | < 0.02 | < 0.02 |
| Ethyl alcohol (mg/kg) | 3,744 | 2,579 | 3,211 | 4,201 | 2,886 |
| Acetone (mg/kg)  | 99.6 | 62.1 | 56.0 | 49.6 | 12.6 |
| Ethyl acetate (mg/kg) | 4.1 | 4.3 | 4.0 | 3.9 | 6.1 |
| Isopropanol (mg/kg) | 4.5 | < 4.0 | 8.2 | 6.9 | 5.2 |
| Total aerobic microbial count (CFU/g) | < 100 | < 100 | < 100 | < 100 | 20 | 10 | 20 | 10 | 10 |
| Total yeasts/moulds count (CFU/g) | < 10 | 10 | 20 | 10 | < 10 | < 10 | < 10 | < 10 | < 10 |
| Escherichia coli (per 1 g) | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected |

Method of analysis:
- Titration (UPS 921)
- Gravimetry (Ph. Eur. 2.4.16 Method-II)
- ICP-MS (In-house)
- ICP-OES (In-house)
- GC-HSS (UPS 467)

Safety of tetrahydrocurcuminoids from *Curcuma longa* L.
The compositional data on residual solvents (ethyl acetate, acetone, ethanol and isopropanol-Table 1) were found in compliance with Directive 2009/32/EC of the European Parliament and of the Council of 23 April 2009 on the approximation of the laws of the Member States on extraction solvents used in the production of foodstuffs and food ingredients. OJ L 141 6.6.2009, p. 3.

Heavy metals (lead, cadmium and mercury-Table 1) were found to comply with regulatory limits as set in Regulation (EC) No 1881/2006. OJ L 364 20.12.2006.

In addition, analysis of mycotoxins was presented for five batches of the NF, including aflatoxins B1, B2, G1, M1, ochratoxin A, zearalenone and fumonisin B1 and B2 which were analysed and found below regulatory limits as set for various food categories in Regulation (EC) No 1881/2006.

Information was provided on the accreditation of the laboratories that conducted the analyses presented in the application.

The Panel considers that the information provided on the composition is sufficient for characterising the NF.

3.4.1. Stability

The applicant used three independently produced batches of the NF to perform stability tests. The tests were carried out at normal storage conditions at 30°C and at 65% RH for a period of 60 months.

---

### Table 1: Results of the Mycotoxin Analysis

| Parameter (Unit) | #1 | #2 | #3 | #4 | #5 | #6 | #7 | #8 | #9 | #10 |
|------------------|----|----|----|----|----|----|----|----|----|-----|
| **Salmonella** (per 25 g) | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Qualitative method (USP 2022, Ph. Eur. 2.6.31) |
| **Staphylococcus aureus** (per 1 g) | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Qualitative method (USP 2022, Ph. Eur. 2.6.13) |
| **Pseudomonas aeruginosa** (per 1 g) | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Qualitative method (USP 62, Ph. Eur. 2.6.13) |
| **Bile-tolerant Gram-negative bacteria** (per g) | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Not detected | Most Probable Number method (USP 2021, Ph. Eur. 2.6.31) |
| **Coliforms** (CFU/g) | < 10 | < 10 | < 10 | < 10 | < 10 | < 10 | Plate Counting (BAM 2001, 8th edition, chapter 4) |

HPLC-UV: high-performance liquid chromatography-ultraviolet; ICP-MS: inductively coupled plasma-mass spectrometry; ICP-OES: inductively coupled plasma-optical emission spectrometry; GC-HSS: gas chromatography-headspace sampler; USP: US Pharmacopeia; Ph. Eur.: European Pharmacopoeia; BAM: Bacteriological Analytical Manual; CFU: colony forming units.

The compositional data on residual solvents (ethyl acetate, acetone, ethanol and isopropanol-Table 1) were found in compliance with Directive 2009/32/EC. Heavy metals (lead, cadmium and mercury-Table 1) were found to comply with regulatory limits as set in Regulation (EC) No 1881/2006. In addition, analysis of mycotoxins was presented for five batches of the NF, including aflatoxins B1, B2, G1, M1, ochratoxin A, zearalenone and fumonisin B1 and B2 which were analysed and found below regulatory limits as set for various food categories in Regulation (EC) No 1881/2006.

Information was provided on the accreditation of the laboratories that conducted the analyses presented in the application.

The Panel considers that the information provided on the composition is sufficient for characterising the NF.

3 Directive 2009/32/EC of the European Parliament and of the Council of 23 April 2009 on the approximation of the laws of the Member States on extraction solvents used in the production of foodstuffs and food ingredients. OJ L 141 6.6.2009, p. 3.

4 Commission Regulation (EU) No No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in foodstuffs. OJ L 364 20.12.2006.
and at accelerated conditions, at 40°C and at 75% RH, for a period of 6 months. The parameters analysed over the course of the stability studies were loss on drying, total tetrahydrocurcuminoids and microbiological parameters (total aerobic microbial count, total yeast and moulds count, Escherichia coli, Salmonella, Staphylococcus aureus, Pseudomonas aeruginosa and bile-tolerant Gram-negative bacteria).

For all batches analysed at normal and accelerated conditions, no changes were observed for all analysed parameters during the course of the studies. Based on the presented results, the NF does not raise any concern on stability, when packed in food grade sealed containers.

The Panel considers that the data provided sufficient information with respect to the stability of the NF during 60 months of shelf-life at normal storage conditions.

3.5. Specifications

The specifications of the NF are presented in Table 2.

Table 2: Specifications of the NF

| Parameter (unit)                    | Specification       |
|-------------------------------------|---------------------|
| Total tetrahydrocurcuminoids (dry basis) (% w/w) | > 95                |
| Moisture (% w/w)                   | ≤ 1                 |
| Ash (% w/w)                        | ≤ 1                 |
| Palladium (mg/kg)                  | < 5                 |

| Microbiological |                           |
|----------------|---------------------------|
| Total aerobic microbial count (CFU/g) | ≤ 5,000                   |
| Total yeast/moulds count (CFU/g)     | ≤ 100                     |
| Escherichia coli (CFU/g)             | < 10                      |
| Salmonella (in 25 g)                 | Not detected              |
| Staphylococcus aureus (CFU/g)        | < 10                      |
| Coliforms (CFU/g)                    | < 10                      |

w/w: weight per weight; CFU: colony forming units.

The Panel considers that the information provided on the specifications of the NF is sufficient and does not raise safety concerns.

3.6. History of use of the NF and/or of its source

There is no history of use of the NF as a food.

The source, i.e. C. longa rhizomes, that is used for the production of the NF has a long history of use as a spice to flavour and colour food, especially in Indian curries (e.g. Teuscher, 2003; FAO, 2004; Ziegler, 2007; Prasad and Aggarwal, 2011).

Turmeric extract, produced by extraction of dried rhizomes using organic solvents, is a food additive, i.e. curcumin (E 100), authorised in the European Union5.

3.7. Proposed uses and use levels and anticipated intake

3.7.1. Target population

The target population proposed by the applicant is the general adult population excluding pregnant and lactating women.

5 Commission Regulation (EU) No 1129/2011 of 11 November 2011 amending Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council by establishing a Union list of food additives. OJ L 295, 12.11.2011.
3.7.2. Proposed uses and use levels

The applicant intends to market the NF as a food supplement, at a maximum dose of 300 mg per day.

3.7.3. Exposure to undesirable substances

According to the specifications, the NF may contain palladium at < 5 mg/kg. At the proposed conditions of use, the intake of palladium from the NF may thus reach an amount of up to 1.5 µg per day. The Panel notes that this amount is well below the Permitted Daily Exposure (PDE) for palladium of 100 µg per day, as established by the Committee for Human Medicinal Products of the European Medicines Agency (EMA, 2019).

3.8. Absorption, distribution, metabolism and excretion (ADME)

The applicant provided one pharmacokinetic animal study with the NF (Novaes et al., 2017). In this study the NF was dissolved in a mixture of DMSO (2%) and PEG-400 (98%) and administered by gavage to male Sprague–Dawley rats (n = 3) at 500 mg/kg. Blood samples were collected at 0, 15 and 30 min, and 1, 2, 4, 6, 12, 24, 48 and 72 h post-dose. Urine samples were collected at 0, 2, 6, 12, 24, 48 and 72 h post-dose. Serum and urine samples were treated with β-glucuronidase to release any glucuronide conjugates. A rapid absorption with an average serum tetrahydrocurcumin Cmax of 6.8 µg/mL at 1 h was observed, followed by a short elimination phase. This was followed by two smaller tetrahydrocurcumin maxima of about 1 µg/mL at 6 and 24 h, respectively. The total amount of tetrahydrocurcumin excreted in urine was 8 µg at 24 h, which did not further increase until the end of the study (72 h). The presence of tetrahydrocurcumin in urine, even though at low concentrations, indicates oral absorption to some degree and elimination at least in part through the renal route (Novaes et al., 2017).

The applicant also provided an overview of the metabolism of curcumin and curcuminoids as described in the literature. Tetrahydrocurcumin is one of the metabolites of curcumin, produced in vivo through Phase I metabolism in the liver by hepatic reductases. Similar to other reduced curcumin metabolites, tetrahydrocurcumin is conjugated with glucuronide (via glucuronyltransferases) or sulfate (via sulfotransferases), resulting in tetrahydrocurcumin glucuronoside (about 30% (Fança-Berthon et al., 2021)) or corresponding monosulfate. Excretion occurs primarily via the biliary system and, to a lesser extent, via the urinary system (Holder et al., 1978; Heger et al., 2014; Jäger et al., 2014). Based on this information, it can be assumed that the NF is mainly excreted via the bile.

3.9. Nutritional information

The applicant provided nutritional information for five batches of the NF. Small quantities of fats (0.22–0.29%), moisture (0.19–0.35%), ash (0.03–0.05%) and sodium (0.001–0.002%) were detected. Proteins and carbohydrates (including fibre and starch) were not detected (however, limits of detection for proteins and carbohydrates, 0.27 and 2.7 g/kg, respectively, were high).

The Panel considers that, taking into account the composition of the NF, which consists of > 95% tetrahydrocurcuminoids, and the proposed conditions of use, consumption of the NF is not nutritionally disadvantageous.

3.10. Toxicological information

The applicant provided six toxicological studies. These studies, which were claimed proprietary by the applicant, are listed in Table 3.
The studies were conducted in accordance with respective OECD (Organisation for Economic Co-operation and Development) test guidelines (TG) No 471, 487, 408, 421 (OECD, 1997, 2016a,b, 2018) and in compliance with principles of Good Laboratory Practice (GLP) (OECD, 1998). For one bacterial reverse mutation assay (Indian Institute of Toxicology, 2004, unpublished) no GLP certificate but a signed statement of compliance with GLP was provided by the laboratory, which appears to be accredited by NABL (National Accreditation Board for Testing and Calibration Laboratories, India).

### 3.10.1. Genotoxicity

The applicant submitted two bacterial reverse mutation tests (Indian Institute of Toxicology, 2004, unpublished; Innovis, 2012, unpublished) and one in vitro mammalian erythrocyte micronucleus test (Bioneeds India Private Limited, 2019, unpublished). The full study reports and certificates of analysis of the test items were provided.

In the originally submitted bacterial reverse mutation test (Innovis, 2012, unpublished), a test item was used which was produced by a manufacturing process that is not fully in compliance (i.e., isopropyl alcohol was used instead of ethyl acetate) with the production process of the NF as presented under section 3.3. Concentrations up to 1,250 µg/plate were tested for potential mutagenicity using the *Salmonella* Typhimurium tester strains TA98, TA100, TA102, TA1535 and TA1537. The highest dose of 1,250 µg/plate was chosen based on solubility and precipitation tests. There were no increases in the number of revertant colonies, neither in the presence or absence of metabolic activation (S9-mix).

Following an EFSA request for additional information and clarification on the test item in the study described above, the applicant submitted an additional bacterial reverse mutation test (Indian Institute of Toxicology, 2004, unpublished). In this test, the NF (containing 95.3% tetrahydrocurcuminoids) was tested at various concentrations up to 5,000 µg/plate. The *S. Typhimurium* tester strains TA98, TA98, TA100, TA1535 and TA102 were used, and the plate incorporation method was applied. The NF up to the highest concentration tested did not induce increases in revertant colonies, with or without metabolic activation (S9-mix).

The in vitro mammalian erythrocyte micronucleus test (Bioneeds India Private Limited, 2019, unpublished) was performed in human lymphocytes with a batch of the NF that contained 95.1% tetrahydrocurcuminoids. In the initial cytotoxicity test, the test item was applied at concentrations of 0.0625, 0.125, 0.25, 0.5 and 1 mg/mL. As there was excessive cytotoxicity (84.8% and 96.7%,
respectively) observed at the two highest concentrations, these were not applied in the main experiment. Thus, concentrations of 0.0625, 0.125 and 0.25 mg/mL were used (for short term treatment in the presence and absence of metabolic activation (S9-mix), for long term treatment in the absence of metabolic activation). At the highest dose (i.e. 0.25 mg/mL) tested in the main experiment, cytotoxicity amounted to 38.3% (short term treatment plus S9-mix), 43.3% (short term treatment without S9-mix) and 41.7% (long term treatment without S9-mix). There was no increase in the percentage of micronuclei at any of the tested concentrations compared to the vehicle control, both with and without metabolic activation.

Taking into account the test results provided, the Panel considers that there are no concerns regarding genotoxicity of the NF.

3.10.2. Acute and subchronic toxicity

The summary report of an acute oral toxicity study was provided (Indian Institute of Toxicology, 2003, unpublished), for which Sprague-Dawley rats (5/sex) received once by gavage 2,000 mg/kg body weight (bw) of the NF. All animals survived the 14-day observation period. The Panel considers that acute toxicity studies are, in general, of limited relevance for the safety assessment of NFs.

A 90-day repeated dose oral toxicity study with the NF was provided (Vipragen Biosciences, 2016a (unpublished study report); Majeed et al., 2019). The study included a 14-day recovery period. Adult Wistar rats (10/group and sex for the main groups; 5/group and sex for the recovery groups) were administered by gavage 0 (vehicle only), 100, 200 or 400 mg/kg bw per day of the NF for 90 days. The batch of the NF that was used for this study contained 95.4% tetrahydrocurcuminoids. Carboxymethyl cellulose (0.5%) was used as a vehicle. The rats in the recovery group were kept for 14 days after termination of the treatment.

There was no mortality nor were there any clinical signs observed in any of the study groups during treatment and recovery period. There were no differences in body weight, body weight gain or food consumption between the groups treated with the NF and the control groups. There were no changes in the ophthalmological examination. There were no differences in absolute or relative organ weights between the treated and the control groups. The animals appeared normal from day 1 to the end of observation and did not reveal any functional deficits.

A number of statistically significant differences between control groups and groups that received the NF were observed in the study, which are briefly summarised as follows. A lower blood platelet count was seen in males in the high-dose group compared to the control group. Lymphocytes and monocytes were higher in females in the mid- and high-dose groups when compared to controls, while in males monocytes were lower in the mid- and high-dose groups (compared to controls). Total cholesterol was higher in the high-dose group in males while in females triglycerides were lower in the low-dose group, compared to controls. The Panel considers that the observed differences were small, partly without a clear dose-response relationship, and that they reflect normal biological variation rather than adverse effects.

There were no findings in gross pathology or histopathology, apart from those commonly observed in this rat strain at this age and which were of similar incidence and severity in control and treated animals.

The Panel considers that the no observed adverse effect level (NOAEL) of this study is the highest dose tested, i.e. 400 mg/kg bw per day.

3.10.3. Reproductive and developmental toxicity

A reproduction/developmental toxicity screening test according to OECD TG 421 was provided (Vipragen Biosciences, 2016b (unpublished study report); Majeed et al., 2019).

Adult Wistar rats (10/group and sex) were assigned to four groups that received by gavage 0 (vehicle only), 100, 200 or 400 mg/kg bw per day of the NF. The batch of the NF that was used for this study contained 95.4% tetrahydrocurcuminoids (same batch as for the above 90-day study). The males were administered the NF for 2 weeks prior to mating, during the mating period and thereafter until a total dosing period of 43 days. The females were dosed for 2 weeks prior to mating, through mating, pregnancy and up to lactation day 3. On lactation day 4, pups and dams were sacrificed.

There were no clinical signs or mortality during the study apart from one female in the mid-dose group, which was found dead on gestation day 23 due to dystocia. The mean body weights for males throughout the study and for females up to day 15 did not differ as compared to the control groups. However, during gestation maternal body weight in the high-dose group was statistically significantly
lower (by 6.6–8.6%) than in controls. With respect to food consumption, some statistically significant differences in different directions were observed between groups during some weeks, however without corresponding changes observed in body weights, and hence were not considered relevant.

The mean number of pups, mean body weights of pups, mean litter size, mean viable litter size and day 4 survival index did not significantly differ between the groups. There were no external abnormalities in live or dead pups, apart from tail deformity observed in 9 out of 10 pups of one dam in the low-dose group. This was, however, an isolated finding not observed in the mid- or high-dose group. There were no statistically significant differences for the pre-coital interval, gestation length, male fertility, mating index, female fertility and mating and fecundity index in any of the treated groups when compared to the control groups.

The findings observed in histopathology of reproductive organs and adrenals were of similar incidence and severity in control and treated animals.

Even though reported as not statistically significant, the Panel notes a higher mean post-implantation loss (difference between implantations and live foetuses/pups in percent) of 30.0% in the high-dose group as compared to 15.2%, 12.9% and 16.7% in control, low-dose and mid-dose groups, respectively. The Panel also notes a lower live birth index of 83.1% in the high-dose group as compared to 95.8%, 100% and 98.9% in control, low-dose and mid-dose groups, respectively. This lower live birth index was owing to 14 dead pups (from 4 dams) in the high-dose group, versus 4 dead pups in the control group, 0 in the low-dose group and 1 in the mid-dose group. The Panel considers that these findings may point towards adverse effects of the NF in the high-dose group and, therefore, sets the NOAEL of this study at the mid-dose, i.e. 200 mg/kg bw per day.

3.10.4. Human data

The applicant submitted one open-label, uncontrolled (single arm) study in 20 subjects that received 300 mg (one tablet) of the NF per day for 28 days (Sabinsa Japan Corporation, 2011, unpublished). According to the provided certificate of analysis of the study item, the 300 mg contained 292.2 mg tetrahydrocurcuminoids. All the study participants (5 females and 15 males; mean age 28.3 years; mean body mass index (BMI) = 23.8 kg/m²) completed the study. The endpoints of the study included blood pressure, body weight/BMI, haematology, clinical chemistry and recording of adverse events. No relevant (or statistically significant) changes were found at 28-days compared to baseline. No adverse events were reported during the study. The Panel considers that this uncontrolled study is of little value for the safety assessment of the NF.

3.11. Allergenicity

The NF consists of > 95% of tetrahydrocurcuminoids. Protein was not detected (at a limit of detection of 0.27 mg/g) in the analysis submitted for five batches of the NF.

The Panel considers that the risk of allergic reactions to the NF is low.

4. Discussion

The NF which is the subject of the application is tetrahydrocurcuminoids (> 95%) from turmeric (C. longa L.). The main derivative is tetrahydrocurcumin (average percentage 87%) while tetrahydrodesmethoxycurcumin and tetrahydrobisdesmethoxycurcumin are present in lower amounts (average percentages of 6.4% and 0.3%, respectively).

The applicant intends to market the NF as a food supplement at a maximum dose of 300 mg per day. The target population is adults excluding pregnant and lactating women.

Taking into account the composition of the NF and the proposed conditions of use, consumption of the NF is not nutritionally disadvantageous.

The Panel considers that the NOAEL of the provided 90-day oral toxicity study is the highest dose, i.e. 400 mg/kg bw per day, tested in the study. By applying an uncertainty factor of 200 (10 (interspecies variability) × 10 (intraspecies variability) × 2 (subchronic to chronic study duration)), the Panel derives a safe level of 2 mg/kg bw per day.

The applicant also submitted a reproduction/developmental toxicity screening test, for which the Panel identifies a NOAEL of 200 mg/kg bw per day (i.e. mid-dose as tested in the study). For this study, the Panel considers an uncertainty factor of 100 (10 (interspecies variability) × 10 (intraspecies variability)) as adequate since no adjustment for study duration is required. The Panel thus derives a
safe level of 2 mg/kg bw per day, which is identical to the safe level based on the 90-day toxicity study.

For the target population (adults excluding pregnant and lactating women) with a default body weight of 70 kg (EFSA Scientific Committee, 2012), the safe level of 2 mg/kg bw per day corresponds to 140 mg of the NF per day, which is lower than the use level as proposed by the applicant.

5. Conclusions

The Panel concludes that the NF, tetrahydrocurcuminoids from turmeric (C. longa L.), is safe for the target population at 140 mg/day.

5.1. Request for protection of proprietary data in accordance with Article 26 of Regulation (EU) 2015/2283

The Panel could not have reached the conclusion on the safety of the NF under the proposed conditions of use without the following data claimed as proprietary by the applicant: analytical data, bacterial reverse mutation test (Indian Institute of Toxicology, 2004, unpublished), in vitro micronucleus assay (Bioneeds India Private Limited, 2019, unpublished), full study reports of the subchronic toxicity and the reproduction/developmental toxicity screening test (Vipragen Biosciences, 2016a,b; Majeed et al., 2019).

6. Steps taken by EFSA

1) On 29/07/2020, EFSA received a letter from the European Commission with the request for a scientific opinion on the safety of tetrahydrocurcuminoids from turmeric (Curcuma longa L.). Ref. Ares(2020)4001815.

2) On 29/07/2020, a valid application on tetrahydrocurcuminoids from turmeric (Curcuma longa L.), which was submitted by Sabinsa Europe GmbH, was made available to EFSA by the European Commission through the Commission e-submission portal (NF 2020/1526) and the scientific evaluation procedure was initiated.

3) On 20/11/2020, EFSA requested the applicant to provide additional information to accompany the application and the scientific evaluation was suspended.

4) On 05/05/2021, additional information was provided by the applicant through the Commission e-submission portal and the scientific evaluation was restarted.

5) On 23/07/2021, EFSA requested the applicant to provide additional information to accompany the application and the scientific evaluation was suspended.

6) On 10/09/2021, additional information was provided by the applicant through the Commission e-submission portal and the scientific evaluation was restarted.

7) During its meeting on 27/10/2021, the NDA Panel, having evaluated the data, adopted a scientific opinion on the safety of tetrahydrocurcuminoids from turmeric (Curcuma longa L.) as a NF pursuant to Regulation (EU) 2015/2283.

References

Bioneeds India Private Limited, 2019 (unpublished, claimed as proprietary by the applicant). Study number Bio-gnt 225. In vitro mammalian cell micronucleus test of C3 reduct® ODN in human lymphocytes. Bioneeds, Karnataka, India. Report date May 20, 2019.

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016. Guidance on the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283. EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594

EFSA Scientific Committee, 2012. Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. EFSA Journal 2012;10(3):2579, 32 pp. https://doi.org/10.2903/j.efsa.2012.2579

EMA (European Medicines Agency), 2018. Committee on Herbal Medicinal Products. Assessment report on Curcuma longa L. rhizoma. EMA/HMPHC/749518/2016. Available online: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-curcuma-longa-l-rhizoma-revision-1_en.pdf

EMA (European Medicines Agency), 2019. International Conference on Harmonisation, ICH Harmonised Guideline, Guideline for Elemental Impurities: Q3D; (R1).

Fança-Berthon P, Tenon M, Le Bouter-Banon S, Manfrè A, Maudet C, Dion A, Chevallier H, Laval J and van Breemen RB, 2021. Pharmacokinetics of a single dose of turmeric curcuminoids depends on formulation: results of a human crossover study. The Journal of Nutrition, 151, 1802–1816.
FAO (World Health Organization), 2004. Curcumin, Chemical and Technical Assessment (CTA). Available online: http://www.fao.org/fileadmin/templates/agns/pdf/jecca/cta/61/Curcumin.pdf
Heger M, van Golen RF, Broeggaard M and Michel MC, 2014. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacological Reviews, 66, 222–307.
Holder GM, Plummer JL and Ryan AJ, 1978. The metabolism and excretion of curcumin (1,7-Bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica, 8, 761–768.
Indian Institute of Toxicology, 2003 (unpublished, claimed as proprietary by the applicant). Project number 9340. The acute oral toxicity (LD50) to Sprague Dawley rat of C30920. Sami Labs Ltd., Bangalore. Report date September 30, 2003.
Indian Institute of Toxicology, 2004 (unpublished, claimed as proprietary by the applicant). Project number 10535. Salmonella typhimurium reverse mutation assay with C31962. Sami Labs Ltd., Bangalore. Report date September 24, 2004.
Innovis, 2012 (unpublished, claimed as proprietary by the applicant). Study number 0782. Bacterial reverse mutation (Ame) screening assay in Salmonella typhimurium strains with tetrahydrocurcuminoids. Ramachandra Innovis, India. Report date December 4, 2012.
Jäger R, Lowery RP, Calvanese AV, Joy JM, Purpura M and Wilson JM, 2014. Comparative absorption of curcumin formulations. Nutrition Journal, 13, 11.
Majeed M, Natarajan S, Pandey A, Bani S and Mundkur L, 2019. Subchronic and reproductive/developmental toxicity studies of tetrahydrocurcumin in rats. Toxicological Research, 35, 65–74.
Novaes J, Lillico R, Sayre C, Nagabushanam K, Majeed M, Chen Y, Ho E, Oliveira A, Martinez S, Alrushaid S, Davies N and Lakowski T, 2017. Disposition, metabolism and histone deacetylase and acetyltransferase inhibition activity of tetrahydrocurcumin and other curcuminoids. Pharmaceuticals, 9, 45.
OECD (Organisation for Economic Co-operation and Development), 1997. Test No. 471: Bacterial reverse mutation test. In: OECD guidelines for the testing of chemicals, Section 4: Health effects, 11 pp.
OECD (Organisation for Economic Co-operation and Development), 1998. OECD Principles of good laboratory practice (as revised in 1997). OECD series on principles of good laboratory practice and compliance monitoring, number 1, ENV/MC/CHM(98)17, 41 pp.
OECD (Organisation for Economic Co-operation and Development), 2016a. Test No. 487: In vitro mammalian cell micronucleus test. In: OECD guidelines for the testing of chemicals, Section 4: Health effects, 29 pp.
OECD (Organisation for Economic Co-operation and Development), 2016b. Test No. 421: reproduction/developmental toxicity screening test. In: OECD guidelines for the testing of chemicals, Section 4: Health effects, 16 pp.
OECD (Organisation for Economic Co-operation and Development), 2018. Test No. 408: Repeated dose 90-day oral toxicity study in rodents. In: OECD guidelines for the testing of chemicals, Section 4: Health effects, 16 pp.
Prasad S and Aggarwal BB, 2011. Turmeric, the golden spice: from traditional medicine to modern medicine. In Benzie IFF and Wachtel-Galor S (eds.). Herbal Medicine: Biomolecular and Clinical Aspects, 2nd Edition. CRC Press/Taylor & Francis, Boca Raton, FL.
Sabinso Japan Corporation, 2011 (unpublished, claimed as proprietary by the applicant). A 28-day safety assessment of tetrahydrocurcuminoids (THC) extract. Clin World Protocol Number: CPL/23/THC/DEC/10. 28 March 2011.
Teuscher E, 2003. Gewürzdrogen. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart. Ein Handbuch der Gewürze, Gewürzkrauter, Gewürzmischungen und ihrer ätherischen Öle. ISBN 3-8047-1867-1.
Vipragen Biosciences, 2016a (unpublished study, claimed as proprietary by the applicant). 90 days repeated dose oral toxicity study of tetrahydrocurcuminoids in Wistar rats with 14 days recovery. Study No. VIP1135. Karnataka, India. 28 January 2016.
Vipragen Biosciences, 2016b (unpublished study, claimed as proprietary by the applicant). Oral (gavage) reproduction/developmental toxicity study of tetrahydrocurcuminoids in Wistar rats. Study No. VIP1136. Karnataka, India. 29 January 2016.
Ziegler H (ed.), 2007. Turmeric, Curcuma. In: Flavourings. Production, Composition, Applications, Regulations. Second completely revised version. Wiley-VCH Verlag GmbH & Co. KGA, Weinheim, 246 pp.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ADME         | absorption, distribution, metabolism and excretion |
| BAM          | Bacteriological Analytical Manual |
| BMI          | body mass index |
| bw           | body weight |
| CAS          | Chemical Abstracts Services |
| CFU          | colony forming units |
| 13C-NMR      | carbon nuclear magnetic resonance |
| CoA          | certificate of analysis |
| DMSO         | dimethyl sulfoxide |
| Acronym | Description |
|---------|-------------|
| EMA     | European Medicines Agency |
| FAO     | Food and Agriculture Organization |
| FSSC    | Food Safety System Certification |
| GC-HSS  | gas chromatography–headspace sampler |
| GLP     | Good Laboratory Practice |
| GMP     | Good Manufacturing Practice |
| HACCP   | Hazard Analysis Critical Control Points |
| HPTLC   | high-performance thin-layer chromatography |
| ICP-MS  | inductively coupled plasma-mass spectrometry |
| ICP-OES | inductively coupled plasma-optical emission spectrometry |
| ISO     | International Organization for Standardization |
| LoD     | limit of detection |
| MW      | molecular weight |
| NABL    | National Accreditation Board for Testing and Calibration Laboratories |
| NDA     | Panel on Nutrition, Novel Foods and Food Allergens |
| NOAEL   | no observed adverse effect level |
| NF      | novel food |
| OECD    | Organisation for Economic Co-operation and Development |
| Pd/C    | palladium on carbon |
| PDE     | permitted daily exposure |
| PEG     | polyethylene glycol |
| Ph. Eur.| European Pharmacopeia |
| RH      | relative humidity |
| TG      | test guidelines |
| USP     | US Pharmacopeia |
| w/w     | weight per weight |